U.S. markets closed

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
11.26+0.14 (+1.26%)
At close: 04:00PM EDT
11.59 +0.33 (+2.93%)
After hours: 05:01PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close11.12
Bid10.95 x 800
Ask11.97 x 1100
Day's Range10.88 - 11.29
52 Week Range7.40 - 18.93
Avg. Volume481,567
Market Cap604.954M
Beta (5Y Monthly)1.01
PE Ratio (TTM)N/A
EPS (TTM)-1.80
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CARA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cara Therapeutics, Inc.
    CARA: What does Argus have to say about CARA?CARA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $7.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022

    Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Therapy recently approved in Canada under the brand name KORSUVA® Regulatory decisions in Australia and Singapore expected by the end of 2022 ST. GALLEN, Switzerland, and STAMFORD, Conn., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA

  • Zacks

    Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

    Cara (CARA) delivered earnings and revenue surprises of 71.43% and 8.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Cara Therapeutics Reports Second Quarter 2022 Financial Results

    – Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia® (difelikefalin) – – KOMFORT Phase 2 trial met primary endpoint in notalgia paresthetica, validating potential broad utility of oral difelikefalin across multiple disease categories; FDA meeting expected in 2H 2022 – – Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Aug. 08, 2022 (GLOBE NEWSWI